OPTN News and Press, OptiNose Inc. From 05/12/22

OptiNose press release (NASDAQ:OPTN): Q1 GAAP EPS of -$0.31. Revenue of $14.76M (+23.4% Y/Y). The Company had cash and cash equivalents of $91.4 million as of March 31, 2022. Corporate Guidance:  The Company expects XHANCE net revenues for the full year of 2022 to be at least $90 million...

Company reports first quarter XHANCE net revenue of $14.8 million increased 35% compared to first quarter 2021 Company expects top-line results from the second of two clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis in June 2022 Conference c...

Conference Call and Webcast to be held May 12, 2022, at 8:00 a.m. Eastern Time YARDLEY, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...

YARDLEY, Pa., April 26, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has appointed R. John Fletcher to its Board of Directors as a Class III director. ...

The primary and secondary endpoints were met in phase 3 clinical trial. The company's revenue was $22.5 million in Q4 2021, up 38% from Q4 2020. The total number of Xhance prescriptions was 93.7 thousand, up 26.8% compared to the previous year. For further details see: O...

OptiNose, Inc. (OPTN) Q4 2021 Earnings Conference Call March 08, 2022, 08:00 AM ET Company Participants Jonathan Neely - Vice President, Investor Relations & Business Operations Peter Miller - Chief Executive Officer Ramy Mahmoud - President & Chief Operating Officer Victor Clavelli -...

The following slide deck was published by OptiNose, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: OptiNose, Inc. 2021 Q4 - Results - Earnings Call Presentation

OptiNose press release (NASDAQ:OPTN): Q4 GAAP EPS of -$0.23 beats by $0.03. Revenue of $22.51M (+37.3% Y/Y) beats by $0.76M. Shares -7.27% PM. Guidance: XHANCE Net Revenue and Average Net Revenue per Prescription.The Company expects XHANCE net revenues for the full year of 2022 to be at least...

Company reports fourth quarter and full year 2021 XHANCE net revenue of $22.5 million and $73.7 million Full year 2021 XHANCE prescriptions increased 28% compared to full year 2020 Company expects XHANCE net revenue for 2022 to be at least $90 million Company...

The commercial-stage pharmaceutical company, Optinose (NASDAQ:OPTN) announced on Monday that its Phase 3 trial for Xhance (fluticasone propionate) met both primary endpoints with statistical significance in patients with chronic sinusitis. Comparing those who received an Exhalation Delivery S...